Jonathan R. Matthias

Array ( [id] => 20592429 [patent_doc_number] => 12576125 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2026-03-17 [patent_title] => Desmopressin oral compositions [patent_app_type] => utility [patent_app_number] => 19/219183 [patent_app_country] => US [patent_app_date] => 2025-05-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 1 [patent_figures_cnt] => 1 [patent_no_of_words] => 51997 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 25 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 19219183 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19860846 [patent_doc_number] => 20250099632 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2025-03-27 [patent_title] => CLEAVABLE RADIOLIGANDS FOR TARGETING CELL SURFACE RECEPTORS AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 18/967265 [patent_app_country] => US [patent_app_date] => 2024-12-03 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 46396 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 113 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18967265 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20547573 [patent_doc_number] => 12558346 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2026-02-24 [patent_title] => Methods and compositions for delivery of biotin to mitochondria [patent_app_type] => utility [patent_app_number] => 18/926573 [patent_app_country] => US [patent_app_date] => 2024-10-25 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 27 [patent_figures_cnt] => 29 [patent_no_of_words] => 15411 [patent_no_of_claims] => 18 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 77 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18926573 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19744021 [patent_doc_number] => 20250032586 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2025-01-30 [patent_title] => STABLE LIQUID COMPOSITIONS OF GLUCAGON [patent_app_type] => utility [patent_app_number] => 18/896310 [patent_app_country] => US [patent_app_date] => 2024-09-25 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 12874 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 99 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18896310 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20254852 [patent_doc_number] => 12427185 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2025-09-30 [patent_title] => Formulations of MANP and uses thereof [patent_app_type] => utility [patent_app_number] => 18/824445 [patent_app_country] => US [patent_app_date] => 2024-09-04 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 53 [patent_figures_cnt] => 101 [patent_no_of_words] => 33114 [patent_no_of_claims] => 39 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 31 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18824445 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20005945 [patent_doc_number] => 20250144167 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2025-05-08 [patent_title] => COMPOSITIONS AND METHODS FOR TARGETING NUCLEAR IMPORT SHUTTLES AND TREATING INFLAMMATORY DISORDERS [patent_app_type] => utility [patent_app_number] => 18/814918 [patent_app_country] => US [patent_app_date] => 2024-08-26 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 12089 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => 0 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18814918 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19541756 [patent_doc_number] => 20240358792 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-10-31 [patent_title] => LIQUID DALBAVANCIN COMPOSITIONS [patent_app_type] => utility [patent_app_number] => 18/770925 [patent_app_country] => US [patent_app_date] => 2024-07-12 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 7323 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 50 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18770925 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19883063 [patent_doc_number] => 12268747 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2025-04-08 [patent_title] => Polypeptides having anti-senescent effects and uses thereof [patent_app_type] => utility [patent_app_number] => 18/674657 [patent_app_country] => US [patent_app_date] => 2024-05-24 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 19 [patent_figures_cnt] => 26 [patent_no_of_words] => 27219 [patent_no_of_claims] => 14 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 36 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18674657 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19599620 [patent_doc_number] => 20240390500 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-11-28 [patent_title] => PHARMACEUTICAL COMPOSITION COMPRISING A GLP-1 AGONIST, AN INSULIN AND METHIONINE [patent_app_type] => utility [patent_app_number] => 18/647078 [patent_app_country] => US [patent_app_date] => 2024-04-26 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 11305 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18647078 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19800506 [patent_doc_number] => 20250066431 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2025-02-27 [patent_title] => IDENTIFICATION OF CHANNELRHODOPSIN-2 (CHR2) MUTATIONS AND METHODS OF USE [patent_app_type] => utility [patent_app_number] => 18/639381 [patent_app_country] => US [patent_app_date] => 2024-04-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 12078 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -21 [patent_words_short_claim] => 59 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18639381 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19571861 [patent_doc_number] => 20240376153 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-11-14 [patent_title] => CNP CYCLIC PEPTIDE, AND MEDICINE, EXTERNAL PREPARATION AND COSMETIC EACH CONTAINING SAID CYCLIC PEPTIDE [patent_app_type] => utility [patent_app_number] => 18/626956 [patent_app_country] => US [patent_app_date] => 2024-04-04 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 31320 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18626956 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19737203 [patent_doc_number] => 12214010 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2025-02-04 [patent_title] => Desmopressin oral compositions [patent_app_type] => utility [patent_app_number] => 18/625923 [patent_app_country] => US [patent_app_date] => 2024-04-03 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 1 [patent_figures_cnt] => 1 [patent_no_of_words] => 58406 [patent_no_of_claims] => 22 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 69 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18625923 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19448930 [patent_doc_number] => 20240309060 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-09-19 [patent_title] => POLYPEPTIDE BAX/NPM INHIBITORS [patent_app_type] => utility [patent_app_number] => 18/606396 [patent_app_country] => US [patent_app_date] => 2024-03-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 30996 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -26 [patent_words_short_claim] => 23 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18606396 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19737250 [patent_doc_number] => 12214059 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2025-02-04 [patent_title] => Cleavable radioligands for targeting cell surface receptors and uses thereof [patent_app_type] => utility [patent_app_number] => 18/604400 [patent_app_country] => US [patent_app_date] => 2024-03-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 8 [patent_figures_cnt] => 8 [patent_no_of_words] => 46331 [patent_no_of_claims] => 13 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 1087 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18604400 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20083707 [patent_doc_number] => 20250213643 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2025-07-03 [patent_title] => COMPOSITIONS AND METHOD FOR OPTIMIZED PEPTIDE VACCINES USING RESIDUE OPTIMIZATION [patent_app_type] => utility [patent_app_number] => 18/602513 [patent_app_country] => US [patent_app_date] => 2024-03-12 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 250849 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -26 [patent_words_short_claim] => 167 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18602513 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19432524 [patent_doc_number] => 20240301022 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-09-12 [patent_title] => GLYCOPROTEINS HAVING LIPID MOBILIZING PROPERTIES AND THERAPEUTIC USES THEREOF [patent_app_type] => utility [patent_app_number] => 18/598878 [patent_app_country] => US [patent_app_date] => 2024-03-07 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 30545 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 18 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18598878 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19497657 [patent_doc_number] => 20240336675 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-10-10 [patent_title] => C3B INACTIVATING POLYPEPTIDE [patent_app_type] => utility [patent_app_number] => 18/438008 [patent_app_country] => US [patent_app_date] => 2024-02-09 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 21578 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18438008 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19613204 [patent_doc_number] => 20240398884 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-12-05 [patent_title] => PLANT MESSENGER PACKS ENCAPSULATING POLYPEPTIDES AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 18/402297 [patent_app_country] => US [patent_app_date] => 2024-01-02 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 54765 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18402297 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19657069 [patent_doc_number] => 20240424134 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-12-26 [patent_title] => PEPTIDE HAVING INDEPENDENTLY STABILIZED HYDROPHOBIC ALPHA HELIX, PEPTIDE COMPLEX COMPRISING SAME AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 18/517548 [patent_app_country] => US [patent_app_date] => 2023-11-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 21689 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -22 [patent_words_short_claim] => 53 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18517548 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19316823 [patent_doc_number] => 20240238363 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-07-18 [patent_title] => ORAL PEPTIDE ANTAGONISTS OF MULTIPLE CHEMOKINE RECEPTORS FOR REVERSING LOSS OF SYNAPSES AND DENDRITIC SPINES [patent_app_type] => utility [patent_app_number] => 18/512201 [patent_app_country] => US [patent_app_date] => 2023-11-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 4706 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -9 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18512201 [rel_patent_id] =>[rel_patent_doc_number] =>)